Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial

Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target.

The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning.

Eli Lilly‘s stock rose 2.1% in premarket trading.

Novo is exploring additional trials to test CagriSema, including higher-dose combinations, it said.

This is breaking news. Please refresh for updates.

Source

World

Tech stocks could offer their best value in years, analysts say, after stellar earnings season

May 8, 2026

Jakub Porzycki | Nurphoto | Getty Images U.S. tech stocks are back in vogue after another stellar earnings season, but Morningstar analysis suggests the sector offers the best value to investors in years. Market chatter in 2024 and 2025 frequently referenced fears of a “bubble” emerging in the top end of the U.S. equity market, […]

World

CNBC Daily Open: Leadership challenge swirls around Starmer

May 8, 2026

U.K. Prime Minister Keir Starmer leaves Downing Street on February 02, 2026 in London, United Kingdom. Alishia Abodunde | Getty Images News | Getty Images Hello, this is Leonie Kidd writing to you from London. Welcome to another edition of CNBC’s Daily Open. It’s a tough time to go to the polls. That’s what U.K. […]

World

Why pension funds are doubling down on private credit despite deepening cracks

May 8, 2026

Pension funds are sticking with private credit, and in some cases doubling down on allocations even as concerns mount over underwriting standards, valuation opacity and sector concentration. Institutional investors, including pension funds, “generally remain committed to the asset class, with many continuing to build out their allocations,” said Cameron Systermans, head of multi-asset at Mercer […]